New antipsychotic medications in the last decade

M Pahwa, A Sleem, OH Elsayed, ME Good… - Current Psychiatry …, 2021 - Springer
Abstract Purpose of Review Over the last ten years, the treatment of psychosis has seen a
near explosion of creative development in both novel agents and new delivery modalities …

[HTML][HTML] Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes

L Citrome, MA Mychaskiw, A Cortez… - Innovations in Clinical …, 2023 - ncbi.nlm.nih.gov
Objective The complexity inherent in the treatment of schizophrenia results in a multitude of
outcome assessments being employed when conducting clinical trials. Subjective outcome …

Conventional and retrospective change in health-related quality of life of trauma patients: an explorative observational follow-up study

JA Haagsma, I Spronk, MAC de Jongh… - Health and quality of life …, 2020 - Springer
Background Within trauma care measurement of changes in health-related quality of life
(HRQL) is used in understanding patterns of recovery over time. However, conventionally …

An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder

J Faden, C Ramirez, V Martinez… - Expert Review of …, 2024 - Taylor & Francis
Introduction Long-acting injectable (LAI) antipsychotic medications can help improve
treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they …

Newer formulations of risperidone: role in the management of psychotic disorders

I Clark, D Taylor - CNS drugs, 2020 - Springer
Antipsychotic long-acting injections improve relapse prevention in psychotic disorders.
Three new risperidone formulations have been developed that offer advantages over …

An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

DP Walling, SN Shinde, JM Pogoda, J Kharidia… - Clinical Drug …, 2024 - Springer
Abstract Background and Objective Long-acting injectable antipsychotics have shown
benefits over oral medications with reduced hospitalization rates and improved health …

Once-monthly subcutaneously administered risperidone in the treatment of schizophrenia: patient considerations

LV Tchobaniouk, EE McAllister, DL Bishop… - Patient preference …, 2019 - Taylor & Francis
Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting
injectable antipsychotics have been shown to offer advantages over oral formulations. A …

Процена Утицаја Антипсихотика На Коштани Метаболизам и Карактеристике Телесног Састава Болесника Са Схизофренијом

АП Корићанац - 2023 - search.proquest.com
Процена утицаја антипсихотика на коштани метаболизам и карактеристи Page 1
УНИВЕРЗИТЕТ У КРАГУЈЕВЦУ Факултет медицинских наука Александра П …

Procena uticaja antipsihotika na koštani metabolizam i karakteristike telesnog sastava bolesnika sa shizofrenijom

AP Korićanac - Универзитет у Крагујевцу, 2023 - nardus.mpn.gov.rs
Uvod: Podaci iz literature pokazuju da terapija antipsihoticima može da utiče na koštani
metabolizam kod pacijenata sa shizofrenijom. Cilj: Naš cilj je bio da utvrdimo uticaj različitih …

[PDF][PDF] Risdiplam (Evrysdi)

R Team - Canadian Journal of Health Technologies, 2021 - canjhealthtechnol.ca
Risdiplam (Evrysdi) Page 1 November 2021 Volume 1 Issue 11 Clinical Review
Pharmacoeconomic Review CADTH Reimbursement Review Risdiplam (Evrysdi) Sponsor …